Adaptive Biotechnologies Corp 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company at a critical inflection point. Adaptive has successfully proven that its clonoSEQ product can scale rapidly and generate positive Adjusted EBITDA at the segment level, but this has not yet translated to consolidated GAAP profitability. The widening gap between segment-level success and corporate-level losses highlights the ongoing burden of R&D and the structural cost of its unique financing arrangements. Ultimately, the investment case hinges on whether the MRD business can scale fast enough to offset the burn from the Immune Medicine platform and the revenue-interest obligations. While the growth in test volumes is an undeniable positive signal, the lack of positive operating cash flow suggests that the 'cash cow' narrative is still in its early stages and remains subject to reimbursement risks and execution hurdles in target discovery.